Abbvie Inc (NYSE:ABBV) Sellers Declined By 3.51% Their Shorts

AbbVie Inc. (NYSE:ABBV) Corporate Logo

During 2018 Q2 the big money sentiment increased to 0.94. That’s change of 0.24, from 2018Q1’s 0.7. 55 investors sold all, 614 reduced holdings as AbbVie Inc. ratio improved. 524 grew positions while 107 funds bought positions. Funds hold 1.00 billion shares thus 5.08% less from 2018Q1’s 1.06 billion shares.
Cadinha And Lc has invested 0.38% in AbbVie Inc. (NYSE:ABBV). Moreover, Psagot Inv House Limited has 0.08% invested in AbbVie Inc. (NYSE:ABBV) for 18,650 shs. Kessler Inv holds 1.16% or 10,426 shs. Ww Asset Management Inc accumulated 108,206 shs. Art Ltd Liability Corp holds 0.01% in AbbVie Inc. (NYSE:ABBV) or 3,400 shs. Johnson Fincl Group holds 0.24% or 23,350 shs in its capital. Nuveen Asset Mgmt Ltd Company accumulated 270,115 shs or 0.16% of the stock. Broderick Brian C holds 20,605 shs. Proshare Advsr Limited reported 966,984 shs. Chicago Equity Prtnrs Limited Liability accumulated 228,065 shs. Acropolis Investment Mngmt Llc reported 2,336 shs. Tudor Inv Et Al stated it has 149,167 shs. Jnba Fincl Advisors owns 0.2% invested in AbbVie Inc. (NYSE:ABBV) for 10,175 shs. Todd Asset Lc reported 373,781 shs. Ancora Advsr Llc holds 37,284 shs or 0.15% of its capital.

AbbVie Inc. registered $9.85 million net activity with 2 insider buys and 3 insider sales since June 15, 2018. Another trade for 42,450 shs valued at $3.82M was made by Gosebruch Henry O on Thursday, November 29. On Friday, June 15 RICHMOND TIMOTHY J. sold $1.75 million worth of AbbVie Inc. (NYSE:ABBV) or 17,588 shs. RAPP EDWARD J bought 1,013 shs worth $99,909. Shares for $4.88M were sold by SEVERINO MICHAEL on Friday, August 17.

Abbvie Inc (NYSE:ABBV) showed a decrease of 3.51% in shares shorted. FINRA published in December ABBV’s total 31.44M shares shorted. That’s 3.51% down from 32.58M shares. 8 days will cost ABBV with 4.02M average volume to recover its previous position. Abbvie Inc’s shares shorted float is 2.08%.

ABBV touched $86.96 during the last trading session after $3.37 change.AbbVie Inc. has 6.74M shares volume, 24.69% up from normal. ABBV is uptrending and has moved 6.26% since December 8, 2017. ABBV underperformed the S&P500 by 9.36%.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide.The firm is worth $130.81 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.The P/E ratio is 18.16. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

A total of 5 analysts rate AbbVie (NYSE:ABBV) as follows: 2 “Buy”, 1 “Hold” and 2 “Sell”. Š¢herefore 40% are bullish. (NYSE:ABBV) has 8 ratings reports on Dec 8, 2018 according to StockzIntelligence. In Monday, June 11 report Argus Research maintained the stock with “Buy” rating. On Friday, June 22 the firm has “Sell” rating given by Credit Suisse. On Thursday, October 4 the stock has “Buy” rating by Bank of America. On Monday, November 5 the rating was maintained by BMO Capital Markets with “Underperform”. On Wednesday, August 22 the firm earned “Buy” rating by Bank of America. On Monday, July 30 the company was maintained by Bank of America. On Tuesday, November 6 the firm has “Buy” rating by Argus Research given.

For more AbbVie Inc. (NYSE:ABBV) news brought out briefly go to:,,, or The titles are as follows: “AbbVie’s elagolix successful in late-stage uterine fibroid studies – Seeking Alpha” brought out on November 15, 2018, “SunTrust: Venclexta could add $1B+ for AbbVie – Seeking Alpha” on November 23, 2018, “AbbVie (ABBV) Phase 3 Trial of Rova-T Halted After Shorter Overall Survival –” with a publish date: December 05, 2018, “AbbVie terminates enrollment in late-stage study of Rova-T in lung cancer on safety signal; shares down 2% premarket – Seeking Alpha” and the last “AbbVie and Roche’s venetoclax shows long-term treatment benefit in late-stage leukemia study – Seeking Alpha” with publication date: December 02, 2018.

AbbVie Inc. (NYSE:ABBV) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.